![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
M Ohtani, H Kotaki, Y Sawada and T Iga
Department of Pharmacy, University of Tokyo Hospital, Faculty of Medicine, Japan.
The relationships between plasma or brain concentrations and analgesic effects of both buprenorphine (BN) and an active metabolite, norbuprenorphine (NBN), were investigated in rats. Maximal analgesic effects measured by a tail flick test were obtained at 10 and 30 min after intravenous (i.v.) administration of BN (8 micrograms/kg dose) and NBN (100 micrograms/kg dose), respectively. No correlation was observed between analgesic effect and the early plasma BN or NBN concentrations. However, at latency times, the concentration of BN in the plasma, cerebellum and the rest of the brain (including the brainstem, midbrain and cerebrum) was related in a counterclockwise hysteresis fashion to analgesia. There was no relationship between the estimated specific binding concentration of BN in the brain and the analgesic effects. After i.v. administration of BN or NBN, the analgesic effect of NBN was approximately one-fiftieth that of BN. The n-octanol/water partition coefficient of NBN was one-tenth that of BN. Further, the results of intraventricular administration of each drug suggested that the intrinsic analgesic activity of NBN was one-fourth that of BN. From these findings, we conclude that the remarkably weak pharmacological effect of NBN after i.v. administration may be due not only to the low permeability of NBN into the brain but also to its small intrinsic pharmacological effect.
This article has been cited by other articles:
|
|
 |
|
  A. Yassen, J. Kan, E. Olofsen, E. Suidgeest, A. Dahan, and M. Danhof Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory-Depressant Effect of Buprenorphine and Fentanyl in Rats J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 682 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chang, D. E. Moody, and E. F. McCance-Katz NOVEL METABOLITES OF BUPRENORPHINE DETECTED IN HUMAN LIVER MICROSOMES AND HUMAN URINE Drug Metab. Dispos., March 1, 2006; 34(3): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yassen, E. Olofsen, A. Dahan, and M. Danhof Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1136 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Grabovsky and R. J. Tallarida Isobolographic Analysis for Combinations of a Full and Partial Agonist: Curved Isoboles J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 981 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Gueye, S. W. Borron, P. Risede, C. Monier, F. Buneaux, M. Debray, and F. J. Baud Lack of Effect of Single High Doses of Buprenorphine on Arterial Blood Gases in the Rat Toxicol. Sci., July 1, 2001; 62(1): 148 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ohmori, T. Hayashi, M. Kawase, S. Saito, and Y. Morimoto Pharmacokinetic and Pharmacodynamic Evaluations of a Potent Analgesic, Dihydroetorphine, in Hairless Rat J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 528 - 536. [Abstract] [Full Text]
|
|
|
|
|
|
P. Huang, G. B. Kehner, A. Cowan, and L.-Y. Liu-Chen Comparison of Pharmacological Activities of Buprenorphine and Norbuprenorphine: Norbuprenorphine Is a Potent Opioid Agonist J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 688 - 695. [Abstract] [Full Text]
|
|
|
|
|
|
M. Valle, M. J. Garrido, J. M. Pavón, R. Calvo, and I. F. Trocóniz Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effects of Main Active Metabolites of Tramadol, (+)-O-Desmethyltramadol and (-)-O-Desmethyltramadol, in Rats J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 646 - 653. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Garrido, M. Valle, R. Calvo, and I. F. Trocóniz Altered Plasma and Brain Disposition and Pharmacodynamics of Methadone in Abstinent Rats J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 179 - 187. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. T. Everhart, P. Cheung, P. Shwonek, K. Zabel, E. C. Tisdale, P. Jacob III, J. Mendelson, and R. T. Jones Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: application to pharmacokinetics of sublingual buprenorphine Clin. Chem., December 1, 1997; 43(12): 2292 - 2302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ohtani, H. Kotaki, K. Nishitateno, Y. Sawada, and T. Iga Kinetics of Respiratory Depression in Rats Induced by Buprenorphine and its Metabolite, Norbuprenorphine J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 428 - 433. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
